RUNX antibodies (RUNX1. RUNX2. RUNX3) are essential tools for studying the RUNX family of transcription factors, which play critical roles in development, differentiation, and disease. RUNX proteins bind DNA through a conserved Runt domain and regulate target genes by interacting with co-factors like CBFβ. RUNX1 (AML1) is crucial for hematopoiesis and is frequently mutated in leukemia. Antibodies against RUNX1 are widely used to study its role in blood cell development, leukemogenesis, and megakaryocytic differentiation. RUNX2 is a master regulator of osteoblast differentiation and skeletal development. Its antibodies help investigate bone formation, chondrocyte maturation, and pathological conditions like cleidocranial dysplasia or osteosarcoma. RUNX3. initially linked to neurogenesis, is also involved in immune regulation and gastrointestinal development. RUNX3 antibodies are utilized to explore its tumor-suppressive functions in gastric cancer and regulatory roles in T-cell differentiation.
These antibodies enable detection of RUNX protein expression, localization, and interactions via techniques like Western blot, immunohistochemistry, and ChIP-seq. Commercial antibodies vary in specificity across isoforms and post-translationally modified forms, requiring careful validation. Their applications extend to developmental biology, cancer research, and regenerative medicine, with RUNX proteins serving as potential biomarkers or therapeutic targets.